News
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
The collaboration revenue from net sales of zurzuvae was $36.1 million for the full year 2024 and $13.8 million for the first ...
Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...
Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...
Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...
Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...
The Nasdaq climbed 1.52% to 19,701.21, and the Dow Jones added 0.8%, closing at 42,515.09, supported in part by gains across the banking sector.
Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 million. Shares in Sage shot up by 35% amid the news by midday Monday, while ...
Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results